The results of phase II clinical study of new hepatitis B drug paradofovir mesylate

On the morning of September 16, 2019, the press conference of phase II clinical research results of the national "13th five year plan" major new drug development target hepatitis B new drug, paradofovir mesylate, undertaken by Xi'an Xintong Pharmaceutical Research Co., Ltd was held in the report hall on the first floor of Shaanxi Provincial Department of science and technology At the meeting, Niu Junqi, vice president of the first hospital of Jilin University, the clinical responsible unit, made a detailed interpretation of the phase II clinical data of the drug: after 24 weeks of treatment, the HBV DNA viral load decreased, the percentage of viral load not detected, and the negative rate of HBeAg positive were better than that of the TDF group, and the overall incidence of side effects was lower than that of the TDF group, no renal and skeletal toxicity trend was found Potential, showing the huge advantage of hepdirecttm liver targeting technology At the same time, the second generation liver targeted hepatitis B drug HTS developed by the company and Guangdong Qifang Pharmaceutical Co., Ltd using this technology has officially entered phase I clinical trial The early animal test shows that the virus does not rebound after the short-term drug withdrawal, suggesting that there may be a long-term treatment effect, so that we expect a greater surprise.